NASDAQ:AVEO - AVEO Pharmaceuticals Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $18.00
Forecasted Upside: 242.86 %
Number of Analysts: 4
Breakdown:
0 Sell Ratings
0 Hold Ratings
4 Buy Ratings
0 Strong Buy Ratings

^$5.25 As of 08/2/2021 01:00 AM ET

▲ +0.08 (1.55%)

1 month | 3 months | 12 months

Get New AVEO Pharmaceuticals Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for AVEO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AVEO

^$18.00

▲ +242.86% Upside Potential

This price target is based on 4 analysts offering 12 month price targets for AVEO Pharmaceuticals in the last 3 months. The average price target is $18.00, with a high forecast of $26.00 and a low forecast of $9.00. The average price target represents a 242.86% upside from the last price of $5.25.

Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in AVEO Pharmaceuticals. This rating has held steady since March 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations Description Skip Past Price Target Consensus Chart

0 strong buy ratings
2 buy ratings
0 hold ratings
1 sell ratings

Ratings as of

2/9/2020

0 strong buy ratings
3 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/9/2020

0 strong buy ratings
4 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

8/7/2020

0 strong buy ratings
4 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

11/5/2020

0 strong buy ratings
5 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

2/3/2021

0 strong buy ratings
5 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/4/2021

0 strong buy ratings
4 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

7/3/2021

0 strong buy ratings
4 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

8/2/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
7/12/2021	HC Wainwright	Lower Price Target	Buy	$27.00 ➝ $19.00	High
3/17/2021	HC Wainwright	Reiterated Rating	Buy		Low
3/11/2021	SVB Leerink	Boost Price Target	Outperform	$10.00 ➝ $18.00	High
3/9/2021	SVB Leerink	Reiterated Rating	Buy		Low
1/19/2021	SVB Leerink	Boost Price Target	Outperform	$7.00 ➝ $10.00	Medium
11/12/2020	HC Wainwright	Reiterated Rating	Buy		Medium
11/9/2020	Stifel Nicolaus	Initiated Coverage	Buy	$9.00	High
9/2/2020	Piper Sandler	Reiterated Rating	Overweight	$26.00	Low
8/13/2020	SVB Leerink	Initiated Coverage	Outperform	$7.00	High
6/1/2020	HC Wainwright	Reiterated Rating	Buy	$10.00 ➝ $12.00	High
5/29/2020	Piper Sandler	Boost Price Target	Overweight	$18.50 ➝ $26.00	High
5/29/2020	Robert W. Baird	Boost Price Target	Positive ➝ Outperform	$15.00 ➝ $24.00	High
5/1/2020	HC Wainwright	Reiterated Rating	Buy	$6.00 ➝ $10.00	High
4/1/2020	Piper Sandler	Lower Price Target	Overweight	$20.00 ➝ $18.50	High
4/1/2020	HC Wainwright	Reiterated Rating	Buy	$4.00 ➝ $6.00	High
3/18/2020	HC Wainwright	Boost Price Target	Buy	$1.75 ➝ $4.00	High
11/4/2019	Piper Jaffray Companies	Lower Price Target	Overweight	$40.00 ➝ $20.00	High
10/1/2019	HC Wainwright	Reiterated Rating	Buy	$17.50	Medium
9/11/2019	HC Wainwright	Upgrade	Neutral ➝ Buy	$10.00 ➝ $17.50	Medium
9/10/2019	Piper Jaffray Companies	Boost Price Target	Overweight	$30.00 ➝ $40.00	High
3/28/2019	National Securities	Initiated Coverage	Sell		High
3/18/2019	HC Wainwright	Reiterated Rating	Hold	$10.00	High
2/4/2019	B. Riley	Reiterated Rating	Buy ➝ Neutral	$50.00 ➝ $10.00	High
2/1/2019	HC Wainwright	Downgrade	Buy ➝ Neutral	$10.00	High
1/31/2019	Piper Jaffray Companies	Reiterated Rating	Overweight	$50.00 ➝ $30.00	High
1/14/2019	HC Wainwright	Reiterated Rating	Buy	$90.00	High
1/8/2019	B. Riley	Initiated Coverage	Buy	$50.00	Low
1/3/2019	Robert W. Baird	Initiated Coverage	Outperform ➝ Outperform	$30.00	High
12/20/2018	(FBRC)	Set Price Target	Buy	$30.00	Medium
12/13/2018	HC Wainwright	Set Price Target	Buy	$90.00	High
11/6/2018	National Securities	Downgrade	Buy ➝ Neutral		High
11/6/2018	HC Wainwright	Set Price Target	Buy ➝ Buy	$90.00	High
10/23/2018	HC Wainwright	Set Price Target	Buy	$70.00	High
8/16/2018	HC Wainwright	Initiated Coverage	Buy	$65.00	Medium
1/16/2018	B. Riley	Reiterated Rating	Buy	$50.00	High
11/13/2017	B. Riley	Initiated Coverage	Buy ➝ Buy	$50.00	N/A
10/6/2017	Seaport Global Securities	Reiterated Rating	Buy		N/A
8/28/2017	Piper Jaffray Companies	Boost Price Target	Overweight	$38.00 ➝ $45.00	High
8/10/2017	Piper Jaffray Companies	Reiterated Rating	Buy	$35.00	Low
7/13/2017	(FBRC)	Reiterated Rating	Outperform	$30.00	High
6/30/2017	(FBRC)	Reiterated Rating	Buy	$30.00	Low
6/24/2017	Piper Jaffray Companies	Set Price Target	Buy	$20.00	High
6/23/2017	Piper Jaffray Companies	Reiterated Rating	Positive		High
5/22/2017	(FBRC)	Reiterated Rating	Outperform	$30.00	High
4/17/2017	(FBRC)	Reiterated Rating	Outperform	$30.00	High
4/8/2017	(FBRC)	Reiterated Rating	Buy		Low
3/25/2017	(FBRC)	Reiterated Rating	Outperform	$30.00	Medium
2/27/2017	(FBRC)	Reiterated Rating	Outperform	$30.00	N/A
9/13/2016	(FBRC)	Reiterated Rating	Buy		N/A
8/8/2016	(FBRC)	Reiterated Rating	Buy		N/A

(Data available from 8/2/2016 forward)

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the treatment of RCC. The company has also completed a Phase II clinical trial of tivozanib in combination with Opdivo (nivolumab) for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor that is in a Phase II clinical trial for the treatment of squamous cell carcinoma of the head and neck, pancreatic cancer, and acute myeloid leukemia; AV-203, a potent humanized IgG1 monoclonal antibody, which completed Phase I clinical trial for treating human ErbB3; and AV-380, a potent humanized IgG1 inhibitory monoclonal antibody that is in a Phase I clinical trial for the treatment or prevention of cachexia. The company's preclinical stage product includes AV-353 that targets the Notch 3 pathway. AVEO Pharmaceuticals, Inc. has collaboration agreements with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; Kyowa Kirin Co., Ltd.; AstraZeneca PLC; and Bristol Myers Squibb. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $5.25

$5.10

$5.28

50 Day Range

MA: $6.35

$5.12

$7.34

52 Week Range

Now: $5.25

$4.25

$18.24

Volume

214,449 shs

Average Volume

1,408,540 shs

Market Capitalization

$180.40 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.19

Frequently Asked Questions

What sell-side analysts currently cover shares of AVEO Pharmaceuticals?

The following Wall Street analysts have issued stock ratings on AVEO Pharmaceuticals in the last twelve months: HC Wainwright, Piper Sandler, Stifel Nicolaus, SVB Leerink LLC, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for AVEO.

What is the current price target for AVEO Pharmaceuticals?

4 Wall Street analysts have set twelve-month price targets for AVEO Pharmaceuticals in the last year. Their average twelve-month price target is $18.00, suggesting a possible upside of 242.9%. Piper Sandler has the highest price target set, predicting AVEO will reach $26.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $9.00 for AVEO Pharmaceuticals in the next year.
View the latest price targets for AVEO.

What is the current consensus analyst rating for AVEO Pharmaceuticals?

AVEO Pharmaceuticals currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AVEO will outperform the market and that investors should add to their positions of AVEO Pharmaceuticals.
View the latest ratings for AVEO.

What other companies compete with AVEO Pharmaceuticals?

Other companies that are similar to AVEO Pharmaceuticals include Amgen, Gilead Sciences, Regeneron Pharmaceuticals, Vertex Pharmaceuticals, Biogen, Alexion Pharmaceuticals, Seagen, Alnylam Pharmaceuticals, Exact Sciences, Incyte, BioMarin Pharmaceutical, Repligen, Novavax, Neurocrine Biosciences and United Therapeutics.

How do I contact AVEO Pharmaceuticals' investor relations team?

AVEO Pharmaceuticals' physical mailing address is 30 WINTER STREET, BOSTON MA, 02108. The biopharmaceutical company's listed phone number is 857-400-0101 and its investor relations email address is [email protected] The official website for AVEO Pharmaceuticals is www.aveooncology.com.